---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-26-000003"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:41:16.147529+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Amneal expects to meet or exceed FY2025 guidance; net leverage improves to 3.6x

## Summary
- Net revenue guidance $3.0B-$3.1B; Adj EBITDA $675M-$685M; Adj diluted EPS $0.75-$0.80.
- Operating cash flow guided at $300M-$330M; capex ~$100M
- Net leverage estimated at 3.6x as of Dec 31, 2025, down from 3.9x at Dec 31, 2024.
- Company reaffirms guidance originally provided on Oct 30, 2025; expects to meet or exceed targets.

## SEC filing metadata
- accession: 0001723128-26-000003
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000003/0001723128-26-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312826000003/amrx-20260113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-26-000003
- JSON: https://secwatch.observer/filing/0001723128-26-000003.json
- Plain text: https://secwatch.observer/filing/0001723128-26-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.